FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  CICIC DRAGAN
2. Date of Event Requiring Statement (Month/Day/Year)
06/20/2024		 3. Issuer Name and Ticker or Trading Symbol
SELLAS Life Sciences Group, Inc. [SLS]
(Last)
(First)
(Middle)
C/O SELLAS LIFE SCIENCES GROUP, INC.,, 7 TIMES SQUARE, SUITE 2503		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP, Chief Development Officer
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)

NEW YORK, NY 10036		 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 118,584 (1)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(Month/Day/Year) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (2) 03/12/2030 Common Stock 35,000 $ 1.89 D  
Stock Option (Right to Buy)   (3) 03/04/2031 Common Stock 47,250 $ 8 D  
Stock Option (Right to Buy)   (4) 01/31/2032 Common Stock 48,750 $ 5.34 D  
Stock Option (Right to Buy)   (5) 02/02/2033 Common Stock 55,000 $ 3.34 D  
Stock Option (Right to Buy)   (6) 01/22/2034 Common Stock 65,000 $ 0.5195 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
CICIC DRAGAN
C/O SELLAS LIFE SCIENCES GROUP, INC.,
7 TIMES SQUARE, SUITE 2503
NEW YORK, NY 10036		       SVP, Chief Development Officer  

Signatures

/s/ Dragan Cicic 06/27/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Consists of (i) 28,116 shares of Common Stock and (ii) 90,468 restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25,000 RSUs shall vest upon the satisfaction of performance-based vesting requirements, and 65,468 RSUs shall vest in one-quarter (1/4) increments annually on December 1 of each year provided that the Reporting Person remains in service with the Issuer through each such annual vesting date.
(2) One-quarter (1/4) of the option shares vested and became exercisable one year from the March 12, 2020 grant date, and the remainder vested and became exercisable in equal monthly installments for thirty-six (36) months thereafter.
(3) One-quarter (1/4) of the option shares vested and became exercisable one year from the March 4, 2021 grant date, and the remainder vested, or will vest, and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
(4) One-quarter (1/4) of the option shares vested and became exercisable one year from the January 31, 2022 grant date, and the remainder vested, or will vest, and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
(5) One-quarter (1/4) of the option shares vested and became exercisable one year from the February 2, 2023 grant date, and the remainder vested, or will vest, and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
(6) One-quarter (1/4) of the option shares will vest and become exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
 
Remarks:
Exhibit List - Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.